Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Identification of Novel HLA Class II-Restricted Neoantigens Derived from Driver Mutations.

Iiizumi S, Ohtake J, Murakami N, Kouro T, Kawahara M, Isoda F, Hamana H, Kishi H, Nakamura N, Sasada T.

Cancers (Basel). 2019 Feb 24;11(2). pii: E266. doi: 10.3390/cancers11020266.

2.

Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitor.

Matsuo N, Azuma K, Hattori S, Ohtake J, Kawahara A, Ishii H, Tokito T, Yamada K, Shibata Y, Shimokawaji T, Kondo T, Kato T, Saito H, Yamada K, Sasada T, Hoshino T.

Int J Cancer. 2019 Mar 1;144(5):1170-1179. doi: 10.1002/ijc.31923. Epub 2018 Nov 12.

PMID:
30307035
3.
4.

Are peptide vaccines viable in combination with other cancer immunotherapies?

Ohtake J, Sasada T.

Future Oncol. 2017 Aug;13(18):1577-1580. doi: 10.2217/fon-2017-0136. Epub 2017 Aug 4. No abstract available.

PMID:
28776424
5.

Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy.

Kitamura H, Ohno Y, Toyoshima Y, Ohtake J, Homma S, Kawamura H, Takahashi N, Taketomi A.

Cancer Sci. 2017 Oct;108(10):1947-1952. doi: 10.1111/cas.13332. Epub 2017 Aug 23. Review.

6.

Current status and future prospects of peptide-based cancer vaccines.

Wada S, Yada E, Ohtake J, Fujimoto Y, Uchiyama H, Yoshida S, Sasada T.

Immunotherapy. 2016 Nov;8(11):1321-1333. Review.

PMID:
27993087
7.

Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment.

Sasada T, Azuma K, Ohtake J, Fujimoto Y.

Front Pharmacol. 2016 Oct 26;7:405. eCollection 2016. Review.

8.

IL-6 down-regulates HLA class II expression and IL-12 production of human dendritic cells to impair activation of antigen-specific CD4(+) T cells.

Ohno Y, Kitamura H, Takahashi N, Ohtake J, Kaneumi S, Sumida K, Homma S, Kawamura H, Minagawa N, Shibasaki S, Taketomi A.

Cancer Immunol Immunother. 2016 Feb;65(2):193-204. doi: 10.1007/s00262-015-1791-4. Epub 2016 Jan 12.

PMID:
26759006
9.

Neuropeptide signaling through neurokinin-1 and neurokinin-2 receptors augments antigen presentation by human dendritic cells.

Ohtake J, Kaneumi S, Tanino M, Kishikawa T, Terada S, Sumida K, Masuko K, Ohno Y, Kita T, Iwabuchi S, Shinohara T, Tanino Y, Takemura T, Tanaka S, Kobayashi H, Kitamura H.

J Allergy Clin Immunol. 2015 Dec;136(6):1690-1694. doi: 10.1016/j.jaci.2015.06.050. Epub 2015 Sep 12. No abstract available.

PMID:
26371842
10.

IL-11 induces differentiation of myeloid-derived suppressor cells through activation of STAT3 signalling pathway.

Sumida K, Ohno Y, Ohtake J, Kaneumi S, Kishikawa T, Takahashi N, Taketomi A, Kitamura H.

Sci Rep. 2015 Sep 1;5:13650. doi: 10.1038/srep13650.

11.

Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.

Ohtake J, Ohkuri T, Togashi Y, Kitamura H, Okuno K, Nishimura T.

Immunol Lett. 2014 Sep;161(1):20-30. doi: 10.1016/j.imlet.2014.04.010. Epub 2014 Apr 30.

PMID:
24794408
12.

Identification of a meiosis-specific protein, MEIOB, as a novel cancer/testis antigen and its augmented expression in demethylated cancer cells.

Shiohama Y, Ohtake J, Ohkuri T, Noguchi D, Togashi Y, Kitamura H, Nishimura T.

Immunol Lett. 2014 Mar-Apr;158(1-2):175-82. doi: 10.1016/j.imlet.2014.01.004. Epub 2014 Jan 16.

PMID:
24440806
13.
14.

First clinical trial of cancer vaccine therapy with artificially synthesized helper/ killer-hybrid epitope long peptide of MAGE-A4 cancer antigen.

Takahashi N, Ohkuri T, Homma S, Ohtake J, Wakita D, Togashi Y, Kitamura H, Todo S, Nishimura T.

Cancer Sci. 2012 Jan;103(1):150-3. doi: 10.1111/j.1349-7006.2011.02106.x.

Supplemental Content

Loading ...
Support Center